Sir

I read with interest the article entitled: “IgE, COX-2, and IL-4 are Expressed by DEHP through p38 MAPK and Suppressed by Plant Glycoprotein (75 kDa) in ICR Mice” Inflammation, vol. 34, no. 5, October 2011 [1]. This article is quite interesting and the authors should be complimented for the great amount of work they have done. The purpose of this letter is to call attention to the need for some clarification on the name of the plant described in this article. Oh et al. state: “Korean herbal plant Cudrania tricuspidata Bureau (CTB) has been traditionally used for treating gastritis, liver damage, and inflammation in Korea”. I have been studying the pharmacotoxicological properties of the medicinal plants of Asia and the Pacific for the last 15 years [2–6] and the sole medicinal member of the family Moraceae officially recognised in China and Korea are Antiaris, Artocapus, Broussonetia, Fatoua, Ficus, Maclura, Malaisia, Morus and Streblus [7]. Cudrania tricuspidata (family Moraceae) does not exist in Korea and is not a “Korea herbal plant”.